Search

Your search keyword '"Riely, Gregory J."' showing total 607 results

Search Constraints

Start Over You searched for: Author "Riely, Gregory J." Remove constraint Author: "Riely, Gregory J." Language english Remove constraint Language: english
607 results on '"Riely, Gregory J."'

Search Results

1. Automated real-world data integration improves cancer outcome prediction

3. Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors

4. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor[FIGURE DASH]Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

7. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification

8. Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis

9. Genomic mapping of metastatic organotropism in lung adenocarcinoma

11. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

12. Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers

13. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer.

16. Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions

18. SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas

21. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

23. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes

26. Single-Cell Sequencing Illuminates Thymic Development: An Updated Framework for Understanding Thymic Epithelial Tumors.

27. YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics

29. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants

30. Tumor mutational load predicts survival after immunotherapy across multiple cancer types

35. Effects of KRAS Genetic Interactions on Outcomes in Cancers of the Lung, Pancreas, and Colorectum.

36. Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors

39. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

41. Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.

42. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease

44. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

47. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

50. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial

Catalog

Books, media, physical & digital resources